Cipla launches India’s only inhaled insulin, Afrezza

31 December 2025

India’s Cipla Limited (BSE: 500087) announced the launch of Afrezza (insulin human) Inhalation Powder in India.

Cipla had obtained regulatory approval from Central Drugs Standard Control Organization (CDSCO) late last year, for the exclusive distribution and marketing of Afrezza, a rapid-acting orally inhaled insulin, which offers a needle-free, convenient alternative to injectable insulin therapy. The launch of this product in India is expected to benefit many of the 10 crore adults currently living with diabetes mellitus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK